ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced on March 27 2026 that it will deregister its securities with the Securities and Exchange Commission and discontinue all public reporting requirements. The decision, made by the Board of Directors, signals a strategic shift toward a private ownership structure and a departure from the public market’s regulatory framework.
The company’s letter to shareholders explains that remaining a public reporting company is a “significant and ongoing financial burden.” ZIVO’s cash balance of $57,222 is dwarfed by an estimated $6 million annual burn, and the company has repeatedly raised capital through notes, stock issuances, and loans. The board concluded that the cost of maintaining public status outweighs the benefits, and that too much capital is flowing to third parties to sustain the public listing rather than to build the business.
As a result of deregistration, ZIVO’s shares will be removed from public exchanges, ending the ability to trade on OTCQB. Shareholders will receive formal notification of the transition and any potential impact on share value. The company’s prior delisting from Nasdaq and subsequent move to OTCQB underscore the ongoing liquidity challenges that prompted this decision.
ZIVO’s management highlighted that the company is at an inflection point in its AgTech vertical and anticipates meaningful revenue from its product line in the coming months. The company also plans to pursue private financing or a strategic partnership to secure the capital needed to sustain operations. The deregistration timeline will be completed in accordance with SEC filing requirements, after which the company will operate as a private entity.
The announcement reflects a broader trend of companies exiting public markets to reduce compliance costs and focus on growth opportunities. For ZIVO, the move is intended to preserve shareholder value by eliminating dilution from repeated public‑market financing and to position the company for future private capital raises or partnerships.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.